46th week of 2012 patent applcation highlights part 47 |
Patent application number | Title | Published |
20120289501 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls - The invention relates to new derivatives of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a proliferative disease. | 2012-11-15 |
20120289502 | IMIDAZOLE DERIVATIVES - A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): | 2012-11-15 |
20120289503 | AQUEOUS SOLUTION COMPRISING 3 - QUINUCLIDINONES FOR THE TREATMENT HYPERPROLIFERATIVE, AUTOIMMUNE AND HEART DISEASE - A liquid composition that is an aqueous solution of a compound of formula (I), wherein the aqueous solution has a pH from about 3.0 to about 5.0. The liquid composition may be used in the treatment of a disorder selected from hyperproliferative diseases, autoimmune diseases and heart diseases. | 2012-11-15 |
20120289504 | Benzoimidazole Compounds and Uses Thereof - This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes. | 2012-11-15 |
20120289505 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE - The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof. | 2012-11-15 |
20120289506 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - 5-membered heterocyclic derivatives represented by general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH | 2012-11-15 |
20120289507 | ORGANIC COMPOUNDS AS SMO INHIBITORS - The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action involve methods of inhibiting tumorigenesis, tumor growth and tumor survival using agents that inhibit the Hedgehog and Smo signaling pathway. | 2012-11-15 |
20120289509 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR - Provided are novel heterocyclic compounds useful as anti-cancer drugs by suppressing protein kinase activities of growth factor receptors such as c-Met, pharmaceutical compositions containing the same, and methods for using the compound. | 2012-11-15 |
20120289510 | Benzyl Amines, A Process For Their Production And Their Use As Anti-Inflammtory Agents - The present invention relates to the compounds of formula I, | 2012-11-15 |
20120289511 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE - The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same. | 2012-11-15 |
20120289512 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme - The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids. | 2012-11-15 |
20120289513 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES - The present invention relates to compounds of formula (I) | 2012-11-15 |
20120289514 | PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCY - Pharmaceutical composition for treating alcohol dependence in humans comprising two active ingredients:
| 2012-11-15 |
20120289515 | Combination therapy for cognitive distortions, resisting relapse of unipolar non-psychotic depression - The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and/or using the method for smoking cessation or nicotine withdrawal. | 2012-11-15 |
20120289516 | Methods for Administering Aripiprazole - The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres. | 2012-11-15 |
20120289517 | SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - The present invention relates to a solid pharmaceutical composition for oral administration, containing the following components (A) and (B): (A) | 2012-11-15 |
20120289518 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME - The present invention relates to derivatives of 4-{2-[phenyl-3,6-dihydropyridin-1-yl]-2-oxoalkyl}-1-piperazin-2-one and 4-{2-[phenyl-2,5-dihydropyrrol-1-yl]-2-oxoalkyl}-1-piperazin-2-one having general formula (I): | 2012-11-15 |
20120289519 | PROTEASE INHIBITORS - Compounds of the formula II: | 2012-11-15 |
20120289520 | CHEMICAL COMPOUNDS 785 - DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity | 2012-11-15 |
20120289521 | Treatment of Acne and Other Diseases - The invention relates to compounds for the treatment of dermatological diseases where inflammation, matrix metalloproteinases (MMPs) and peroxisome proliferator-activated receptors (PPARs) play a role in mediating the disease, such as the treatment of acne with Pemirolast or a closely related compound thereof. | 2012-11-15 |
20120289522 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 2012-11-15 |
20120289523 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION - The invention relates to novel compounds useful in the treatment and prophylaxis of disease. Compounds of the formula (I) wherein X is halogen, independently selected form chlorine and fluorine and n is 0, 1 or 2, and their pharmaceutically acceptable salts are useful in the treatment and prophylaxis of diseases caused by activation of microglia, particularly Alzheimer's disease. | 2012-11-15 |
20120289524 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION - The invention relates to novel compounds useful in the treatment and prophylaxis of disease. Compounds of the formula (I): | 2012-11-15 |
20120289525 | PYRIMIDINE ETHER DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Pyrimidine Ether Derivatives, compositions comprising a Pyrimidine Ether Derivative, and methods of using the Pyrimidine Ether Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G-protein coupled receptor (GPCR) in a patient. | 2012-11-15 |
20120289526 | IMIDAZOLIDINEDIONE DERIVATIVES - The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizophrenia, substance abuse disorders, sleep disorders or epilepsy. | 2012-11-15 |
20120289527 | MONO-HYDROCHLORIC SALTS OF AN INHIBITOR OF HISTONE DEACETYLASE - This invention provides novel crystalline forms of mono-HCl salts and a mono-HCl salt hydrate of JNJ-26481585, an inhibitor of histone deacetylases. The invention also relates to processes for production of these forms, to intermediates used in these processes, to pharmaceutical compositions comprising these forms, and to the use of these forms in medical treatment for instance as a medicine to inhibit proliferative conditions, such as cancer and leukemia. | 2012-11-15 |
20120289528 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY - The present invention relates to a regimen for the administration of a pyrimidylaminobenzamide of formula I | 2012-11-15 |
20120289532 | METHOD FOR THE PRODUCTION OF AMORPHOUS RIFAXIMIN - The present invention relates to a new amorphous form of rifaximin and to methods for the preparation thereof by means of high energy milling or Spray drying. The present invention further relates to a new amorphous form for use as medicament and to the pharmaceutical compositions composing it. | 2012-11-15 |
20120289533 | Use of Manzamine Compounds in Anti-Cancer Therapeutic Regimens - Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion and tumor metastasis as well in restoring cancer cell susceptibility to standard chemotherapeutic agents which induce apoptosis and, therefore, has utility in treating cancer. | 2012-11-15 |
20120289534 | PACKAGE FOR IMPROVED TREATMENT OF CONDITIONS - The present invention provides an improved package from the administration of active ingredients. The present invention provides a package comprising: a standard portion comprising one or more active ingredients in a plurality of different potencies, and a rescue portion comprising one or more same or different active ingredients. The package may be optionally be used with a patient assessment module. The present invention also provides a kit comprising: a package comprising a standard portion comprising one or more active ingredients in a plurality of different potencies, and a patient assessment module comprising instructions for administration of the standard portion. The package may optionally further comprise a rescue portion. | 2012-11-15 |
20120289535 | DUAL PHASE DRUG RELEASE SYSTEM - The present invention relates to conjugate comprising a carrier substituted with one or more occurrences of a moiety having the structure: | 2012-11-15 |
20120289536 | Pharmaceutical Compositions Comprising Colloidal Silicon Dioxide - A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight. | 2012-11-15 |
20120289537 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namelyl, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 2012-11-15 |
20120289538 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 2012-11-15 |
20120289540 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES - The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration. | 2012-11-15 |
20120289541 | METHODS AND COMPOSITIONS FOR APPLYING MOXIFLOXACIN TO THE EAR - Methods and materials useful for applying moxifloxacin to the ear are described. The methods involve delivering a composition that contains at least one viscogenic agent and moxifloxacin or a salt thereof to the epidermal surface of the tympanic membrane via the ear canal. The composition is delivered to the tympanic membrane in a flowable form and, after delivery to the tympanic membrane, becomes sufficiently viscous such that the moxifloxacin is localized against the tympanic membrane. Such compositions can be used to prophylactically and/or therapeutically treat middle and inner ear conditions, including otitis media. | 2012-11-15 |
20120289542 | CICLETANINE IN COMBINATION WITH ORAL ANTIDIABETIC AND/OR BLOOD LIPID-LOWERING AGENTS AS A COMBINATION THERAPY FOR DIABETES AND METABOLIC SYNDROME - Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and an oral antidiabetic agent for treating and/or preventing complications (including microalbuminuria, nephropathies, retinopathies and other complications) in patients with diabetes or metabolic syndrome. | 2012-11-15 |
20120289545 | Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof - The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family. | 2012-11-15 |
20120289546 | MONOHYDROCHLORIDE SALT OF 1-[3-[3-(4-CHLOROPHENYL) PROPOXY]PROPYL]-PIPERIDINE - A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): | 2012-11-15 |
20120289549 | NEW HEXAHYDROPYRROLOIMIDAZOLONE COMPOUNDS - The invention provides novel compounds having the general formula (I), | 2012-11-15 |
20120289550 | COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFERING AGENT, AND METHODS OF USING SAME - The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate. Methods of using such compositions are also provided | 2012-11-15 |
20120289551 | MINERALOCORTICOID RECEPTOR ANTAGONISTS - Mineralocorticoid receptor antagonists, of which the following is exemplary. | 2012-11-15 |
20120289552 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY - This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes. | 2012-11-15 |
20120289553 | ORAL LIQUID PHARMACEUTICAL COMPOSITION OF NIFEDIPINE - It relates to an oral liquid pharmaceutical composition comprising: a) nifedipine in an amount comprised between 0.1% and 1% w/w; b) ethanol in an amount comprised between 38% and 58% w/w; c) water in an amount comprised between 4% and 12% w/w; d) glycerine in an amount comprised between 30% and 50% w/w; and e) optionally, other pharmaceutical excipients or carriers, the sum total of components being 100% w/w, provided that the composition is substantially free of polyethyleneglycol and derivatives thereof. | 2012-11-15 |
20120289554 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES - This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula | 2012-11-15 |
20120289555 | Novel S-Nitrosoglutathione Reductase Inhibitors - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 2012-11-15 |
20120289556 | Methods for Treating Conditions Caused by Higher-Than-Normal Dopaminergic Activity In Basal Ganglia - Treatment of humans suffering from conditions caused by higher-than-normal dopaminergic activity in basal ganglia includes administering the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl}carbonylmethyl)ureido]phenyl}propionic acid and its physiological acceptable salts. | 2012-11-15 |
20120289557 | Protein Synthesis Required for Long-Term Memory is Induced by PKC Activation on Days Preceding Associative Learning - The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC. | 2012-11-15 |
20120289558 | GAMMA-SECRETASE MODULATORY COMPOUNDS, METHODS FOR IDENTIFYING SAME, AND USES THEREFOR - In accordance with the present invention, it has been discovered that compounds which modulate the γ-secretase enzyme to make more of the shorter, less toxic and less aggregation-prone Aβ peptides (such as Aβ37 and Aβ38), while making less of the longer and more toxic and aggregation-prone AB peptides (such as AB40 and AB42) are useful as gamma-secretase modulators. In addition, these GSM compounds have further been discovered to have the selective property of modulating the formation of various AB peptides, while not inhibiting the overall activity of the γ-secretase enzyme. Thus, such compounds do not impede other critical functions of the γ-secretase enzyme, such as generating fragments from Notch that appear to control gene expression and cell differentiation. Therefore, in accordance with the present invention, there are provided screening assays useful for determining whether test compounds have GSM activity; accordingly, invention assays facilitate the identification of new gamma-secretase modulators. Such screening assays can be performed in a variety of ways, e.g., by assessing whether test compounds: lower the level of Aβ42 peptide, increase the level of Aβ37 and/or Aβ38 peptides, have substantially no effect on the processing of other γ-secretase substrates, and/or interact with at least one component of the γ-secretase complex. Also provided in accordance with the present invention are compounds having gamma-secretase modulatory activity as identified by any of the methods described herein; methods for producing formulations useful for modulating gamma-secretase activity, as well as the resulting formulations; methods for modulating gamma-secretase activity employing compounds identified according to invention methods and/or invention formulations, and the like. | 2012-11-15 |
20120289559 | METHOD FOR PRODUCING FINE POWDER AND THE FINE POWDER PRODUCED BY THE SAME - Disclosed is a manufacturing method for a fine powder exhibiting improved solubility, little impurity contamination, and a high recovery rate. Material to be ground and a grinding medium are suspended and stirred in a liquefied inert gas dispersion medium such as dried ice, and the material to be ground is made into a sub-micron or nano-sized fine powder. A uniform fine powder can be obtained when the material to be ground is a mixture having two or more components. Impurity contamination can be reduced by using granular dry ice as the grinding medium. | 2012-11-15 |
20120289569 | INHIBITORS OF UBIQUITIN E1 - The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention. | 2012-11-15 |
20120289570 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CANCER BY INHIBITING FATTY ACID BINDING PROTEINS - The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins. | 2012-11-15 |
20120289571 | POLYMERIC CONJUGATES OF AROMATIC AMINE CONTAINING COMPOUNDS INCLUDING RELEASABLE UREA LINKER - The present invention relates to releasable urea linker systems involving amine-containing chemical compounds and biologically active agents. In particular, the present invention relates to reversibly releasable linkers based on intramolecular cyclization-assisted releasable urea linkages to aromatic amine-containing compounds. The present invention also relates to polymeric conjugates of indolinone-based tyrosine kinase inhibitors. | 2012-11-15 |
20120289572 | Nicotinic Acetylcholine Receptor Sub-Type Selective Amides of Diazabicycloalkanes - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). | 2012-11-15 |
20120289573 | METHODS FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC TARGETING - The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR). | 2012-11-15 |
20120289574 | HYDRATE CRYSTALS - New (2R,4R) monatin monosodium salt hydrate crystals characterized by having specific characteristic X-ray diffraction peaks provide general-purpose, stable, and safe monatin sodium salt crystals incorporating no organic solvent. These crystal may be prepared by a method that requires no organic solvent in the crystallization, separation, and drying steps. These crystal are useful as sweeteners and for the preparation of orally consumed products, such as foods, beverages, pharmaceutical products, topical pharmaceutical products, and feeds containing general-purpose, stable, and safe monatin sodium salt crystals. | 2012-11-15 |
20120289575 | Topical antimicrobial compositions - Disclosed are topical antimicrobial compositions. The compositions are useful for disinfecting and treating microbial infections of the skin or mucosa of humans and animals. The antimicrobial compositions include a salt of amino acid anion and quaternary ammonium cation, comprising the general formula: | 2012-11-15 |
20120289576 | Process for Forming Amorphous Atorvastatin - A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin. | 2012-11-15 |
20120289577 | COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS - The present invention relates to a composition for treating or preventing hearing loss comprising naphthoquinone-based compounds. | 2012-11-15 |
20120289578 | USE OF RNA INTERFERENCE FOR TREATING OR REDUCING PAIN - A use of a nucleic acid molecule mediating RNA interference for treating or reducing pain is disclosed. The nucleic acid molecule has a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, and is used for effectively inhibiting expression of bradykinin B2 receptor, treating or reducing pain and preparing a pharmaceutical composition for reducing neuropathic pain. | 2012-11-15 |
20120289579 | IMPAIRED WOUND HEALING COMPOSITIONS AND TREATMENTS - Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles. | 2012-11-15 |
20120289580 | ANTISENSE MODULATION OF PTP1B EXPRESSION - Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof. | 2012-11-15 |
20120289581 | DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC USES OF LONG NON-CODING RNAS FOR CANCER AND REGENERATIVE MEDICINE - Long non-coding RNAs (lncRNAs) and methods of using them diagnostically and therapeutically for treatment of cancer, stem cell therapy, or regenerative medicine are disclosed. In particular, the invention relates to lncRNAs that that play roles in regulation of genes involved in cell proliferation, differentiation, and apoptosis. Such lncRNAs can be used as biomarkers to monitor cell proliferation and differentiation during cancer progression or tissue regeneration. One of the identified lncRNAs, referred to as PANDA (a P | 2012-11-15 |
20120289582 | METHODS FOR DIAGNOSING AND TREATING A PATHOLOGY ASSOCIATED WITH A SYNONYMOUS MUTATION OCCURING WITHIN A GENE OF INTEREST - The present invention relates to a method for diagnosing and/or prognosing a pathology (such as inflammatory dis-ease, especially Crohn disease) associated with a synonymous mutation occurring within a gene of interest (such as IRGM, NOD2 or BSN) in a subject and to a method for treating such pathology in a subject. | 2012-11-15 |
20120289583 | TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3) - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Insulin Receptor Substrate 2 (IRS2) polynucleotides, in particular, by targeting natural antisense polynucleotides of Insulin Receptor Substrate 2 (IRS2) polynucleotides and Transcription factor E3 (TFE3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IRS2. | 2012-11-15 |
20120289584 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND COLIPIDS FOR DELIVERING THERAPEUTIC MOLECULES - This disclosure provides compositions that are useful combined with therapeutics, and in the diagnosis and treatment of diseases and conditions. The compositions are useful for delivery of agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects. | 2012-11-15 |
20120289585 | SDF-1 Delivery For Treating Ischemic Tissue - A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification. | 2012-11-15 |
20120289586 | SDF-1 Delivery For Treating Ischemic Tissue - A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification. | 2012-11-15 |
20120289587 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2012-11-15 |
20120289588 | Lipase Inhibitors for the Treatment of Pancreatitis and Organ Failure - The present invention relates to methods for treating pancreatitis and/or organ failure comprising administering, to a subject in need of such treatment, an effective amount of a lipase inhibitor. It is based, at least in part, on the discoveries that lipotoxicity contributes to inflammation, multisystem organ failure, necrotic pancreatic acinar cell death and in acute pancreatitis, and that inhibition of lipolysis was able to reduce indices associated with these conditions. Accordingly, in various embodiments, the present invention provides for methods and compositions for limiting lipotoxicity and thereby reducing the likelihood of poor outcomes associated with acute pancreatitis and other severe systemic conditions, especially in obese individuals. | 2012-11-15 |
20120289589 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives - This invention discloses cannabinoid derivatives and pharmaceutical uses thereof. | 2012-11-15 |
20120289590 | HAIR COSMETIC COMPOSITION - A hair cosmetic composition including an exfoliating agent, an antioxidant, and an antibacterial agent. The hair cosmetic composition is noncomedogenic and nonacnegenic. | 2012-11-15 |
20120289591 | Antimicrobial Compositions Containing Free Fatty Acids - The invention concerns antimicrobial compositions comprising free fatty acids emulsified with membrane lipids or hydrolysed derivatives thereof, and pharmaceutical formulations comprising same. The compositions can be used in the treatment or prophylaxis of microbial infections. They can also regulate the rate of blood clotting rendering them suitable for incorporation in catheter locking solutions and for use in wound care. | 2012-11-15 |
20120289592 | ERCC1 GENE EXPRESSION LEVEL IS ASSOCIATED WITH CLINICAL OUTCOMES IN ESOPHAGEAL CANCER PATIENTS - The disclosure provides compositions and methods for identifying a cancer patient, such as an esophageal cancer patient, suitable for a therapy that includes administration of a platinum drug and radiation pre-operatively, based on the expression level of an ERCC1 gene. After determining if a patient is likely to be successfully treated, the disclosure also provides methods for treating the patients. | 2012-11-15 |
20120289593 | METHODS FOR RISK ASSESSMENT, TREATING, AND DIAGNOSING MYOCARDIAL INFARCTION - This document features method related to genetic markers associated with myocardial infarction. For example, methods of using such genetic markers for risk assessment and for diagnosing and treating myocardial infarction are provided. | 2012-11-15 |
20120289594 | ORAL DOSAGE FORM - An oral dosage form of entacapone and methods for the preparation thereof are provided. | 2012-11-15 |
20120289595 | NOVEL BIARYLAMIDE DERIVATIVE AND COMPOSITIONS CONTAINING THE DERIVATIVE AS AN ACTIVE INGREDIENT - The present invention relates to a novel biarylamide derivative and a pharmaceutical composition or a cosmetic composition comprising the same as an active ingredient. More particularly, the present invention relates to a novel biarylamide derivative, a pharmaceutical composition or a cosmetic composition for preventing or treating a pigmentation disorder caused by an abnormal excess of melanin or a disease caused by melanocyte hyperplasia comprising the same as an active ingredient. The biarylamide derivative of the present invention inhibits melanin production and thus inhibits melanocyte hyperplasia. Therefore, a cosmetic composition comprising the biarylamide is excellent in a whitening effect, and a pharmaceutical composition comprising the biarylamide is effective in the prevention or treatment of pigmentation disorders of skin such as lentigo, melasma, freckle, etc. and malignant melanoma. | 2012-11-15 |
20120289596 | Dermatological Compositions Comprising a Fat or Oil of an Essential Fatty Acid Triglyceride - The present invention relates to a human beta-defensin inducing agent that comprises at least one fat or oil of an essential fatty acid triglyceride or a derivative thereof as the main active ingredient. It also relates to cosmetic, dermatological and pharmacological formulations comprising the at least one fat or oil. | 2012-11-15 |
20120289597 | NITRIC OXIDE AMINO ACID ESTERS FOR THE TREATMENT OF CHRONIC PAIN - There is provided a topical composition and a method for treating or alleviating pain in a patient in need thereof. The topical composition contain amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof and a topical analgesic compound. | 2012-11-15 |
20120289598 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF - The invention encompasses compositions and methods for treating or preventing a degenerative joint condition, wherein the compositions and methods include feeding the companion animal an edible composition including at least one pyruvate or salt thereof. The invention also encompasses methods for enhancing the palatability of an edible food composition including adding a palatability enhancing amount at least one pyruvate or salt thereof to the composition. | 2012-11-15 |
20120289599 | COUPLERS FOR MEDIUM-CHAIN FATTY ACIDS AND DISINFECTING COMPOSITIONS - A disinfecting shower cleaner composition including a medium-chain fatty acid coupled with a nonionic surfactant providing temperature stable antimicrobial compositions. The invention specifically relates to antimicrobial compositions including fatty acid antimicrobial agents coupled with an ethoxylated amine and methods of using the antimicrobial compositions. | 2012-11-15 |
20120289600 | OPTIMIZED STRAINS OF YARROWIA LIPOLYTICA FOR HIGH EICOSAPENTAENOIC ACID PRODUCTION - Engineered strains of the oleaginous yeast | 2012-11-15 |
20120289601 | Gastric Retained Gabapentin Dosage Form - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. | 2012-11-15 |
20120289602 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES - The present invention relates to a pharmaceutical composition and the method of use for treating or preventing burn injury in patients or subjects in need, including the compound represented by the specific chemical formula as an active ingredient or its pharmaceutically acceptable salts or solvates. | 2012-11-15 |
20120289603 | ENHANCED BIMATOPROST OPHTHALMIC SOLUTION - A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein. | 2012-11-15 |
20120289604 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE - Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease. | 2012-11-15 |
20120289605 | METHOD FOR INDUCING UDP-GLUCURONOSYLTRANSFERASE ACTIVITY USING PTEROSTILBENE - A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene. | 2012-11-15 |
20120289606 | Solid Formulations of Liquid Biologically Active Agents - The instant invention relates to a solid product comprising a liquid biologically active agent which is intimately associated to a stabilizing agent; particularly a solid product that can be reconstituted to a clear, stable, stabilized nanodispersion or loaded micelles comprising a polymer as a stabilizing agent and a liquid, preferably water immiscible, biologically active agent. The instant invention is further directed toward a process for the production of the above solid product; particularly to micelles or nanodispersions produced by hydration of a cake or powder of the solid product, produced via an effective treatment of a stabilized solution comprising for example a polymer as a stabilizing agent, such as an amphiphilic block copolymer or a small molecular weight surfactant, loaded with a liquid biologically active agent, such as propofol, an optional additive, and a suitable solvent. | 2012-11-15 |
20120289607 | ABSORBENT COMPOSITION AND METHODS THEREOF - An improved absorbent composition containing biodegradable natural ingredients is described. The composition absorbs liquid quickly, has a large water-absorbing capacity and an excellent water retention capability. The composition enables replacement of a significant amount of less or none biodegradable superabsorbent polymers (SAP) with plant and/or other natural ingredients, while achieving the liquid absorption properties similar to those of the widely used SAPs. The composition can be used as an absorbent in aqueous liquid absorption products, such as disposable personal hygiene products, rendering the products more environmentally friendly. | 2012-11-15 |
20120289608 | BONE CEMENT AND A METHOD FOR PRODUCING SAME - The invention relates to a bone cement composed of a hydrophilic component and a hydrophobic component, wherein biodegradable material is deposited in pores of the bone cement via the hydrophilic component. | 2012-11-15 |
20120289609 | METHODS FOR THE FORMATION OF HYDROGELS USING THIOSULFONATE COMPOSITIONS AND USES THEREOF - The present invention provides both crosslinked polymer compositions capable of forming hydrogels upon exposure to an aqueous environment and thiosulfonate hydrogel-forming components. The thiosulfonate hydrogel-forming components of the invention are preferably multi-arm thiosulfonate polymer derivatives that form a crosslinked polymer composition when exposed to a base without requiring the presence of a second cross-linking reagent, redox catalyst, or radiation. Methods for forming hydrogel compositions, as well as methods for using the hydrogels, are also provided. | 2012-11-15 |
20120289610 | OIL GEL - The present invention relates to the field of oil thickeners and in particular oil gels. Embodiments of the present invention relate for example to a an oil composition containing at least one complex comprising an oil dispersible emulsifier and protein fibres and preparations comprising such oil compositions; the use of such complexes as oil thickeners, and a method to produce the complexes. | 2012-11-15 |
20120289611 | PECTIN COMPOUNDS, METHODS OF USING PECTIN COMPOUNDS, AND METHODS OF CONTROLLING WATER SOLUBILITY - Briefly described, embodiments of the present disclosure provide for compositions including pectin compounds, pectin compounds, methods of making pectin compounds, methods of controlling the water solubility of a pectin compound, methods of controlling the water solubility of an agent, beads including pectin compounds, and the like. | 2012-11-15 |
20120289612 | Composite Material and Method for Producing the Same - It has been necessary to use a relatively large amount of cyclodextrin in order to produce a composite material, but the amount of the cyclodextrin needs to be reduced from the viewpoint of costs; in this respect, the present invention provides a composite material comprising a food or active pharmaceutical ingredient, a phytosterol ester, a medium-chain fatty acid triacylglyceride, and a cyclodextrin. | 2012-11-15 |
20120289613 | EMULSIONS, COMPOSITIONS AND DEVICES INCLUDING GRAPHENE OXIDE, AND METHODS FOR USING SAME - Provided are an emulsion comprising graphene oxide, a first fluid and a second fluid, and a drug delivery system comprising the emulsion. This emulsion is based on the discovery that graphene oxide is an amphiphile with hydrophilic edges and a more hydrophobic basal plane, and thus graphene oxide can act as a surfactant. Since the degree of ionization of the edge —COOH groups of the graphene oxide is affected by pH, the amphiphilicity of graphene oxide can be adjusted based on pH. Therefore, a method of separating a first liquid from a second liquid by providing an emulsion comprising graphene oxide, the first liquid and the second liquid is also provided. It was also discovered that graphene oxide can act as a molecular dispersing agent to process insoluble materials. Based on this discovery, a composition comprising graphene oxide, a solvent and an insoluble solid is provided. | 2012-11-15 |
20120289614 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE - This invention relates to the discovery of functionalized triclosan monomers and oligomers that, when incorporated into a substrate of, or applied as part of a coating to, medical devices and/or consumer products may extend the duration of antimicrobial properties to the medical devices and/or consumer products. | 2012-11-15 |
20120289615 | CATALYST FOR PRODUCING HYDROCARBON FROM SYNGAS AND PRODUCING METHOD OF CATALYST - An exemplary method for producing a catalyst is provided where the catalyst includes a catalyst support on which a metallic compound is loaded. An impurity content of the catalyst can be in a range of approximately 0.01 mass % to 0.15 mass %. In particular, the exemplary method can include pre-treating the catalyst support to lower an impurity concentration of the catalyst support, and loading the metallic compound on the catalyst support after the pretreatment procedure. | 2012-11-15 |
20120289616 | PROCESS FOR STABILIZING FLUOROPOLYMER HAVING ION EXCHANGE GROUPS - The invention pertains to a process for stabilizing a semi-crystalline fluoropolymer comprising ion exchange groups, said process comprising: suspending at least one semi-crystalline fluoropolymer having ion exchange groups [polymer (I)] in at least one fluorinated organic dispersing medium [medium (M)] so as to obtain a dispersion (D) of polymer (I) in a dispersing medium (M); contacting said dispersion (D) with fluorine under irradiation with U. V. radiation so as to obtain a stabilized polymer. Still objects of the invention are a stable semi-crystalline fluoropolymer as above defined having a low amount of unstable ends groups of —COF type, the use of the stabilized fluoropolymer obtained by the process or of the stable fluoropolymer in fuel cells devices, a membrane and a membrane-electrode assembly comprising said fluoropolymers. | 2012-11-15 |
20120289617 | Hybrid Catalyst for Olefin Metathesis - An olefin metathesis catalyst and method for producing same is provided. | 2012-11-15 |
20120289618 | PREPARATION METHOD OF CLAY/POLYMER COMPOSITE USING SUPERCRITICAL FLUID-ORGANIC SOLVENT SYSTEM - The present invention relates to a method for preparing a clay/polymer composite having a predetermined form such as powder or porous foam with an enhanced thermal and mechanical stability using a simple, economical and eco-friendly supercritical fluid-organic solvent system, and more particularly, to a method for preparing a clay/biodegradable polymer stereoisomeric nanocomposite and a clay/polymer composite prepared by the method thereof. The method of preparing a clay/polymer composite according to the present invention may include (a) introducing a clay, a biodegradable single-phase D-type/L-type stereoisomeric polymer and an organic solvent into a reactor, (b) introducing a supercritical fluid into the reactor to form a stereoisomeric composite, and forming a clay/polymer composite dispersed with the clay on the stereoisomeric composite, and (c) collecting the clay/polymer composite, and the clay/polymer composite of the present invention is a clay/polymer composite prepared by the preparation method. | 2012-11-15 |